Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) General Information
Description
Portfolio of inhibitors and intellectual properties. The portfolio include novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and a major unmet medical need.
Contact Information
Corporate Office
- United Kingdom
Corporate Office
- United Kingdom
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) FAQs
-
Where is Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) headquartered?
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) is headquartered in United Kingdom.
-
What industry is Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) in?
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property)’s primary industry is Buildings and Property.
-
Is Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) a private or public company?
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) is a Private company.
-
What is Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property)’s current revenue?
The current revenue for Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) is .
-
Who are Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property)’s investors?
Vantia Therapeutics has invested in Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property).
-
When was Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) acquired?
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) was acquired on 23-Aug-2011.
-
Who acquired Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property)?
Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) was acquired by KalVista Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
